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ABSTRACT: Enterohemorrhagic Escherichia coli (EHEC) serotype O157:H7 strains are associated with haemor-
raghic colitis and haemolytic uremic syndrome (HUS) in humans. Cattle are a reservoir of E. coli O157:H7. We 
studied the ability of bovine and human lactoferrin, two natural antimicrobial proteins present in milk, to inhibit 
E. coli O157:H7 growth and attachment to a human epithelial colorectal adenocarcinoma cell line (Caco-2). The 
direct antibacterial effect of bLF on E. coli O157:H7 was stronger than that of hLF. Nevertheless, both lactofer-
rins had bacteriostatic effects even at high concentrations (10 mg/ml), suggesting blocking of LF activity by a yet 
undefined bacterial defence mechanism. Additionally, both lactoferrins significantly inhibited E. coli O157:H7 
attachment to Caco-2 cells. However, hLF was more effective than bLF, probably due to more efficient binding of 
bLF to intelectin present on human enterocytes leading to uptake and thus removal of bLF from the extracellular 
environment. Inhibition of bacterial attachment to Caco-2 cells was at least partly due to the catalytic effect of 
lactoferrins on the type III secreted proteins EspA and EspB
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The enterohemorrhagic Escherichia coli (EHEC) 
strain O157:H7 is a major food-borne pathogen 
causing severe disease in humans worldwide. 
Healthy cattle are a reservoir of E. coli O157:H7. 
Bovine food products and fresh products con-
taminated with bovine waste are the most com-
mon sources for haemorrhagic colitis (HC) and the 
haemolytic uremic syndrome (HUS) (reviewed by 
Callaway et al., 2009).
Three major virulence factors of E. coli O157:H7 
have been identified including a pathogenicity is-
land called the Locus of Enterocyte Effacement 
(LEE), Shiga toxins (Stx) and the plasmid (pO157) 
encoded enterohaemolysin gene (E-hlyA) that 
codes for a pore-forming cytolysin. E. coli O157:H7 
colonization of the intestinal mucosa induces a his-
topathologic lesion defined as an “attaching and 
effacing” (A/E) lesion characterized by localized 
destruction of brush border microvilli and intimate 
attachment of the bacteria to host cell plasma mem-
branes (Frankel et al., 1998; Karpman et al., 2002). 
The Locus of Enterocyte Effacement (LEE), geneti-
cally governs adhesion and subsequent pathology 
(Nataro and Kaper, 1998). It contains the eae gene, 
encoding the outer membrane protein intimin 
and its receptor Tir (Translocated intimin recep-
tor) (Jerse et al., 1990). In addition, LEE encodes 
proteins of the type III secretion system (TTSS), 
which is made up of an EspA multifilament needle 
complex, used for insertion of the bacterial effec-
tor proteins EspB, EspD and Tir into the host cell. 
Injection of bacterial virulence factors via the TTSS 
and binding of intimin to Tir leads to a strong in-
teraction between bacteria and host cells (Cookson 
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and Woodward, 2003; Vilte et al., 2008). Virulence 
arises also from Shiga toxin production, encoded 
by Shiga toxin genes (stx1 and stx2), which are the 
primary factors responsible for the hemorrhagic 
aspect of diarrhoea and systemic complications 
(HUS). Shiga toxins act as N-glycosidases, cleav-
ing ribosomal RNA leading to the inhibition of host 
cell protein synthesis (Endo et al., 1988).
Most adults recover from E. coli O157:H7 infections 
without sequelae. Children and the elderly however, 
are more likely to experience complications such as 
HUS and even death. The use of antibiotics in treat-
ment for E. coli O157:H7 infections in humans is high-
ly controversial as antibiotics might increase the risk 
of HUS (Safdar et al., 2002; Dundas et al., 2005; Panos 
et al., 2006). Thus, treatment is largely supportive. 
Nonetheless, innovative therapies such as the use of 
probiotics, monoclonal antibodies or recombinant 
bacteria to neutralize or bind toxins, are currently 
being explored (reviewed by Bavaro, 2009).
Natural anti-microbial proteins, such as lacto-
ferrin might assist in the treatment of O157:H7 
infections. Therefore, we examined the effect of 
human and bovine lactoferrin on E. coli O157:H7. 
Lactoferrin (LF) is abundantly present in colos-
trum and milk and belongs to the transferrin fam-
ily. Human colostrum contains 5.3 ± 1.9 mg/ml LF, 
while human milk contains 1 mg/ml LF after the 
first month of lactation. Bovine colostrum contains 
1.5 mg/ml LF and the LF concentration in milk 
ranges from 0.02 mg/ml to 0.20 mg/ml (Shimazaki 
et al., 2000; Ochoa and Cleary, 2009). However, 
large-scale production of bovine LF is relatively 
easy meaning that it is financially feasible, espe-
cially for developing countries.
Lactoferrin exhibits anti-oxidant, antiviral, anti-
inflammatory, immunomodulatory as well as anti-
cancer activities, and interestingly can promote the 
growth of probiotic bacteria such as Bifidobacterium 
(Aguila et al., 2001; Al-Nabulsi and Holley, 2007; 
Jenny et al., 2010; Tsuda et al., 2010; Xu et al., 
2010). Lactoferrin’s bacteriostatic effect is due to 
its ability to bind iron and limit its availability in 
the growth environment (Orsi, 2004). Binding of LF 
to the surface of Gram-negative bacteria initiates 
bactericidal effects by releasing lipopolysaccharide 
(LPS) from the membrane (Ellison et al., 1988; Orsi, 
2004). Additional antimicrobial functions ascribed 
to LF are selective permeation of ions and due to its 
serine protease activity, disruption of the bacterial 
TTSS, thereby blocking bacterial adhesion (Ochoa 
et al., 2003). 
MATERIAL AND METHODS
Organisms and cell culture
The E. coli O157:H7 strain NCTC 12900, a well-
characterized Shiga-toxin negative EHEC strain of 
human origin (Dibb-Fuller et al., 2001) was used 
in both bacterial growth and host cell attachment 
studies. We used this verocytotoxin negative strain 
for biosafety reasons, as in future experiments this 
strain was also going to be used in vivo in rumi-
nants. The non-attaching, E. coli strain DH5α, ex-
tensively used in recombinant DNA technology, 
served as a negative control.
Host cell attachment in the presence and absence of 
LF was evaluated using the Caco-2 human epithelial 
colorectal adenocarcinoma cell line, a well-estab-
lished in vitro model for studying EHEC attachment 
(Izumikawa et al., 1998). Caco-2 cells were seeded into 
24-well flat-bottom plates (Corning Inc., Corning, 
NY) at a density of 1 × 105 cells/well in Dulbecco’s 
modified Eagle’s medium (Gibco, Grand Island, NY) 
containing 1% l-glutamine and 5% heat-inactivated 
fetal bovine serum (Gibco), without antibiotics. Cells 
were grown to confluence at 37°C in a humidified 
atmosphere of 5% CO2 (approximately 72 h).
Recombinant intimin, EspA and EspB
The plasmids pCVD468, pCVD469 and pMW103 
were grown in LB supplemented with Kanamycin 
(25 µg/ml) and Ampicillin (100 µg/ml). Expression 
of EspA, EspB and the C-terminal 380 amino acids 
of intimin-γ (referred to as intimin) was induced by 
adding 1mM isopropyl-β-d-thiogalactopyranoside 
(IPTG). Recombinant His-tagged proteins were pu-
rified by nickel-affinity chromatography (Novagen®) 
and protein concentrations were determined using 
the bicinchoninic acid (BCA) method (Thermo 
Scientific, Rockford, USA).
Lactoferrins
Iron saturated bovine lactoferrin (bLF; Sigma, 
Bornem, Belgium), with 90% purity (SDS-PAGE) 
and > 85% iron saturation purified from bovine 
colostrum, and iron saturated human lactoferrin 
(hLF; Sigma, Bornem, Belgium), with the same 
purity and level of iron saturation, purified from 
human milk were used in this study.
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Effect of lactoferrins on E. coli O157:H7 
growth
E. coli O157:H7 overnight cultures were prepared 
by inoculating a colony isolated in a single well 
into a 10-ml tube containing Luria Bertani broth 
(LB; Becton Dickinson, Claix, France) and incu-
bating the tube at 37°C for 12 to 18 h with shak-
ing (200 rpm). Overnight E. coli O157:H7 cultures 
(1 ml) were pelleted by centrifugation (11 337 × g, 
5 min) and reconstituted in 1 ml of LB medium.
Bacteria (107 CFU/ml) were incubated at 37°C 
for 8 h in LB broth supplemented with different 
concentrations (zero, 0.001, 0.005, 0.01, 0.05, 0.1, 
0.5, 1.0, 5.0 and 10 mg/ml) of human or bovine 
LF. Selected concentrations were within the phys-
iological range. Bacterial growth was monitored 
spectrophotometrically (OD600nm) on the hour for 
8 h subsequently. At the same time, viable bacteria 
were counted by spread plating appropriate bacte-
rial serial dilutions onto LB medium plates. After 
8 h, bacteria were washed three times with LB me-
dium, inoculated into a 10-ml tube containing LB 
broth and incubated at 37°C for 5 h with shaking 
(200 rpm). In addition, we also examined the sur-
face of LF treated bacteria, 1 and 8 h after adding 
LF using scanning electron microscopy (SEM) as 
described by Vandekerckhove et al., (2009). Briefly, 
the bacterial pellets were fixed in a HEPES-buffered 
2% paraformaldehyde-2.5% glutaraldehyde solution 
for 24 h and were critical point dried using CO2 
(CDP 030, Balzers, Sercolab), mounted on metal 
stubs, platinum- coated (JFC-1300 autofine coater, 
Jeol) and finally examined by a Jeal JSM 5600 LV SC. 
El. Microscope (Jeol, Germany).Thus, we studied 
the effect of lactoferrins on bacterial growth but at 
the same time we also defined the maximum hu-
man and bovine lactoferrin concentrations, which 
did not inhibit bacterial growth. These were sub-
sequently used in cell attachment assays.
Lactoferrin cytotoxicity assay
The cell attachment assay was performed using 
Caco-2 cells. To check the putative cytotoxic effect 
of lactoferrins, Caco-2 cells were first seeded in 
96-well plates at a concentration of 5 × 103 cells/ml 
and exposed for 4 h to concentrations of zero, 
0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 5.0 or 10 mg/ml 
human or bovine lactoferrins in culture me-
dium. Incubations were performed in duplicate. 
Cytotoxicity was assessed in a dose dependent man-
ner by the 3-(4,5-dimethylthiazol-2-yl-2,5- diphe-
nyltetrazolium bromide) MTT assay measuring 
mitochondrial activity (Mosmann, 1983). Viable 
cells reduce the tetrazolium salt MTT to a colored 
water-insoluble formazan salt. After it is solubilized, 
formazan can be quantified spectrophotometrically 
at 585 nm. The MTT assay was performed as follows. 
Ten μl MTT (5 mg/ml, Sigma) in Hanks balanced 
salt solution (Invitrogen) was added to each well and 
after 3.5 h of incubation at 37°C, the MTT solution 
was replaced by 200 μl DMSO in ethanol (1/1 v/v). 
The plates were agitated for 15 min on a platform 
shaker (450 RPM) to dissolve the formazan crystals 
and subsequently analyzed spectrophotometrically 
at both 585 nm (OD1) and 620 nm (OD2). The latter 
wavelength was used to correct for cell debris and 
well imperfections. Final optical densities obtained 
from formazan formation were presented as OD1 
minus OD2.
Effect of lactoferrins on E. coli O157:H7 
attachment to Caco-2 cells
The attachment efficiencies of E. coli O157:H7 in 
the presence and absence of lactoferrins were de-
termined by performing attachments assays using 
the Caco-2 human intestinal cell line. Lactoferrins 
were used at the highest concentration which did 
not decrease E. coli O157:H7 growth in LB broth. 
Thus, maximum concentrations of 0.1 mg/ml and 
0.05 mg/ml of human and bovine LF were used, re-
spectively. For each LF, 3 additional lower concen-
trations (0.01, 0.005 and 0.001 mg/ml) were used to 
study concentration-dependent effects. The effect 
of lactoferrins on Caco-2 cells was monitored us-
ing an Olympus IX81 microscope equipped with a 
cell*M Imaging system (Olympus). E. coli O157:H7 
overnight cultures were prepared by inoculating a 
colony isolated in a single well into a 10-ml tube 
containing LB broth and incubating the tube at 37°C 
for 12 to 18 h with shaking (200 rpm). Overnight 
E. coli O157:H7 cultures (1 ml) were pelleted by 
centrifugation (11 337 × g, 5 min) and reconstituted 
in 1 ml of DMEM.
Confluent Caco-2 monolayers were infected with 
E. coli O157:H7 (107 CFU/ml) in the presence or 
absence of different concentrations of bovine or 
human LF and further incubated for 4 h at 37°C 
and 5% CO2. After infection for 4 h at 37 °C, non-
adherent bacteria were removed by washing prepa-
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rations three times with PBS. Caco-2 cells were 
lysed by adding 0.25% trypsin for 15 min (37°C) 
and vigorous pipetting, followed by vortexing of 
the cell suspension. Adherent E. coli O157:H7 cells 
were enumerated by spread plating appropriate se-
rial dilutions onto LB medium plates, in duplicate. 
The LB medium plates were incubated at 37°C for 
24 h, and the resultant CFU were enumerated. The 
attachment efficiency of E. coli O157:H7 was ex-
pressed as a percentage based on the initial inocu-
lum that was recovered as adherent E. coli O157:H7 
cells. The attachment efficiency of each isolate was 
measured in duplicate wells in at least three inde-
pendent experiments (Figure 1).
Effect of lactoferrins on TTSS proteins
Proteolysis of E. coli O157:H7 recombinant in-
timin, EspA and EspB by lactoferrins was deter-
mined as follows. Intimin, EspA and EspB (10 µg/
ml) were incubated in DMEM in the presence or ab-
sence of 10 mg/ml LF for 4 h at 37°C. Subsequently, 
His-labelled fragments were identified by Western 
blotting using a mouse monoclonal antibody against 
histidine (Sigma, Bornem, Belgium). Lactoferrin is 
a member of the serine protease family. Therefore, 
as a control, recombinant proteins were also incu-
bated with lactoferrins (10 mg/ml) in the presence 
of the serine protease inhibitor phenylmethyl sul-
fonyl fluoride (PMSF), (0.25mM) (Sigma, Bornem, 
Belgium), for 4 h at 37°C. Proteolysis was again 
analysed by Western blotting.
Statistics
Statistical analysis was performed by the Proc 
MIXED test using SAS software S version 8.2 (SAS 
Institute Inc., Cary, NC, USA). Results were pre-
sented as mean OD ± SD and mean colony forming 
units (CFU) ± SD for the bacterial growth studies 
and as mean percentages of bacterial attachment 
± SD for the cell attachment study. 
RESULTS
Effect of lactoferrins on E. coli O157:H7 
growth
To determine the effect of LF on E. coli O157:H7 
growth, bacteria were incubated with several con-
centrations of human and bovine LF. Escherichia 
coli O157:H7 growth was significantly inhibited 
from three to six hours post incubation (PI) using 
0.5 to 10 mg/ml and 0.1 to 10 mg/ml of human or 
bovine LF, respectively (Figure 2 and 3). Thus, bLF 
had a stronger inhibitory effect on E. coli O157:H7 
growth than hLF. However, at 8 hours PI, all growth 
curves of LF-treated bacteria and untreated con-
trols reached the same OD value, even at the high-
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Figure 1. Lactoferrin significantly reduced E. coli O157:H7 attachment to Caco-2 cells. Results are represented as the 
mean values ± S.E.M (n = 3). Asterisks indicate statistically significant different between lactoferrins treated groups 
and the control (0 mg/ml lactoferrin) (P < 0.05)
Veterinarni Medicina, 55, 2010 (8): 359–368 Original Paper
363
est LF concentration used. Human and bovine LF 
had no effect on E. coli O157:H7 growth at concen-
trations of 0.1 and 0.05 mg/ml, respectively. After 
8 h, lactoferrins were removed and bacteria were 
allowed to grow again in fresh medium. Resulting 
growth curves were identical to the ones of un-
treated controls (data not shown).
The maximum non-growth-inhibitory concentra-
tions to be used in subsequent cell attachment assays 
were 0.1 mg/ml and 0.05 mg/ml for human or bovine 
LF, respectively. Scanning electron microscopy of bac-
teria incubated with lactoferrins revealed no obvious 
findings except for the presence of significant fewer 
bacteria when using 10 mg/ml bLF (Figure 4). 
Lactoferrin cytotoxicity assay
None of the lactoferrin concentrations tested was 
cytotoxic to Caco-2 cells, as compared to untreated 
control cells (Figure 5). Thus, maximum non-growth-
inhibitory concentrations of lactoferrins could be 
used in a subsequent cell attachment assay.
Effect of lactoferrins on E. coli O157:H7 
attachment to Caco-2 cells
Lactoferrins had no effect on Caco-2 cells 
(Figure 5). In the absence of LF, a mean of 4×104 
0,00E+00
2,00E+09
4,00E+09
6,00E+09
8,00E+09
1,00E+10
1,20E+10
1 2 3 4 5 6 7 8 9
Time (h)
C
FU
10 mg/ml
5 mg/ml
1 mg/ml
0.5 mg/ml
0.1 mg/ml
0.05 mg/ml
0.01 mg/ml
0.005 mg/ml
0 mg/ml
Figure 3. Inhibitory effect of human lactoferrin on the growth of E. coli O157:H7. The results are represented as the mean 
CFU ± S.E.M. (n = 3). Error bars are only shown for the 0.1 mg/ml human lactoferrin. The data in the rectangles are 
significantly different from the control (0 mg/ml human lactoferrin)
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Figure 2. Inhibitory effect of bovine lactoferrin on the growth of E. coli O157:H7. The results are represented as the 
mean CFU ± S.E.M. (n = 3). Error bars are only shown for the 0.05 mg/ml bovine lactoferrin. The data in the rectan-
gles are significantly different from the control (0 mg/ml bovine lactoferrin)
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CFU/well (100%) was recovered from Caco-2 cells. 
In the presence of lactoferrins, E. coli O157:H7 at-
tachment to Caco-2 cells decreased in a concen-
tration-dependent manner (Figure 1). Overall, hLF 
inhibited E. coli O157:H7 attachment more effec-
tively, also at 0.05 mg/ml hLF. At the highest LF 
concentrations used, namely 0.1 mg/ml for hLF and 
0.05 mg/ml for bLF, bacterial attachment was re-
duced by 78% and 57%, respectively, as compared to 
untreated bacteria (100% attachment; P < 0.05).
Effect of lactoferrins on TSSS proteins
Both lactoferrins reduced E. coli O157:H7 at-
tachment to Caco-2 cells significantly at non-
growth-inhibitory concentrations indicating that 
mechanisms other than growth reduction are in-
volved. We examined the effect of LF on the bacte-
rial TTSS of E. coli O157:H7. As shown by Western 
blotting, LF degraded EspA and EspB, but not in-
timin. The proteolytic effect of LF was prevented 
by a serine protease inhibitor.
DISCUSSION
Even though the use of antibiotics for treating 
E. coli O157:H7 infections in humans is typically 
avoided and remains controversial, increasing an-
tibiotic resistance in this bacterium is a concern. 
Several studies have already demonstrated that an-
tibiotic resistant E. coli O157:H7 can be isolated 
from humans, cattle, feed and even from surface 
waters (Schroeder et al., 2002; Fincher et al., 2009). 
Thus, there are several reasons for developing new 
anti-microbial strategies for treatment of human 
infections and preventing E. coli O157:H7 infec-
tions in cattle or at least reduce faecal shedding 
significantly in these animals. Here, we examined 
the effect of human and bovine lactoferrin on E. coli 
O157:H7 growth and on attachment to human cells. 
Figure 4. Scanning electron microscopy of E. coli O157:H7 after eight hours incubation with 10 mg/ml bovine lactoferrin 
(left) and no lactoferrin (right)
Figure 5. Light microscopic view of Caco-2 cells after four hours incubation with 0.1 mg/ml human lactoferrin (left) and 
no lactoferrin (right); bars represent 20 µm
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Growth inhibition was more pronounced when us-
ing bLF. Groenink et al. (1999) reported the same 
findings. Bovine LF inhibited the growth of S. au-
reus, S. mutans, S. sobrinus, S. salivarius as well as 
of E. coli, K. pneumoniae, P. intermedia, P. gingi-
valis, and F. nucleatum, while hLF only inhibited 
growth of S. mutans, S. salivarius and P. interme-
dia (Groenink et al., 1999). Different antimicro-
bial activities could be due to more efficient bLF 
binding to E. coli O157:H7. Naidu et al., (1991) 
studied the binding of hLF and bLF to 169 E. coli 
strains (ETEC and EHEC) isolated from human 
intestinal infections and found large variations in 
the range of 3.7 to 73.4% and 4.8 to 61.6% for hLF 
and bLF, respectively (Naidu et al., 1991). On the 
other hand, the results could also be attributed to 
structural and functional differences between bo-
vine and human LF. The primary structure of bLF 
is 69% identical to hLF, (reviewed by Baker and 
Baker 2005). However, the anti-microbial activity 
resides mainly in the basic N1-domain of lactofer-
rins containing two stretches, designated lactofer-
ricin and lactoferrampin (reviewed by Baker and 
Baker, 2009). Others have reported the same find-
ings. Lactoferricin (25-residue cationic disulphide 
cross-linked peptide of lactoferrins) of bovine 
origin was more active on E. coli (ATCC 25922) 
and S. aureus (ATCC 25923) than lactoferricins 
of human, caprine and murine origin (Vorland et 
al., 1998). The anti-microbial properties of bovine 
lactoferrampin are also stronger than those of their 
human counterparts (Haney et al., 2009).
Nevertheless, none of the lactoferrin concentra-
tions used in our study resulted in 100% cell death. 
To our knowledge 100% cell death has only been ob-
served when using lactoferricin or lactoferrampin, 
which are more potent bacterial killers than the 
larger protein. Bovine lactoferricin and lactofer-
rampin are normally both internalized within a few 
minutes in E. coli K12, concurrently with disruption 
of membrane integrity and killing of E. coli (Van 
der Kraan et al., 2005). However, in the present 
study, CFUs for controls and treated bacteria were 
statistically the same until 2 h and SEM revealed no 
obvious surface changes, which means that bacte-
rial killing by lactoferricin or lactoferrampin is not 
important in our experiment.
Growth inhibition by lactoferrins was significant (at 
0.1 to 10 mg/ml) from 3 to 6 h post incubation. Thus, 
it takes time to notice a significant anti-microbial ef-
fect, which was also observed by Ellison and Giehl 
(1991) and Kawasaki et al. (2000). This could be due 
to the relatively slow interaction of LF with the bacte-
rial LPS, known to result in bacterial killing. Bacterial 
outer membranes are usually asymmetric membranes 
containing the polyanionic glycolipid lipopolysaccha-
ride (LPS) in the outer leaflet and phospholipids in 
the inner leaflet. To stabilize the anionic surface of 
the outer membrane, the LPS is partially neutralized 
by divalent cations, such as Mg2+ and Ca2+. Cationic 
peptides, such as LF-derived anti-microbial peptides 
can interact with the divalent cation-binding sites 
of LPS, thereby distorting the integrity of the outer 
membrane (Chapple et al., 2004).
However, only at high LF concentrations (1.0, 5.0 
and 10 mg/ml) was bacterial growth completely 
arrested for one hour. Thus, at sublethal concen-
trations, human and bovine lactoferrins acted 
bacteriostatically on E. coli O157:H7. The bacteria 
recovered and started to grow again. Chapple et al. 
(2004) observed the same while studying the asso-
ciation of human lactoferricin peptides with E coli 
NCTC 8007 serotype O111. Thus, other events are 
maybe required for lactoferrins to be highly effec-
tive and simply coating the bacterial surface is not 
adequate. On the other hand, E. coli O157:H7 might 
have also developed a bacterial defence system lead-
ing to blockage of lactoferrins. This may explain why 
low and high (1, 5 and 10 ml/ml) LF concentrations 
had no effect or only a temporary growth inhibitory 
effect, respectively. Blockage of LF could be due to 
LPS-mediated shielding of porins from LF interac-
tion (Naidu et al., 1991) and/or to an interaction with 
a bacterial surface protein, as described by Senkovich 
et al., (2007) for the pneumococcal surface protein A 
(PspA). Two helices of PspA bind in grooves in the 
human lactoferrin bactericidal domain and make 
specific interactions with basic residues from helix 
1 and the N-terminus, thereby blocking LF activity 
(Baker and Baker, 2009). However, further research 
is needed to explore this hypothesis.
Lactoferrin and the avian homologue ovotransfer-
rin impair bacterial type III secretion system func-
tion in enteric Gram-negative pathogens (reviewed 
by Ochoa and Cleary, 2009) and the avian respira-
tory pathogen Chlamydophila psittaci (Beeckman 
et al., 2007), thereby decreasing their ability to ad-
here and invade host cells. Both human and bovine 
lactoferrin inhibited E. coli O157:H7 adherence to 
Caco-2 cells in a dose-dependent manner. Overall, 
the anti-adhesive effect of hLF was higher than that 
of bLF. This could be due to the fact that hLF was 
more effective in destroying E. coli O157:H7 viru-
lence factors required for attachment to human cells. 
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Beeckman et al. (2007) described a similar finding. 
Ovotransferrin was more effective than human and 
bovine lactoferrin in preventing attachment and en-
try of Chlamydophila psittaci to avian macrophages 
(Beeckman et al., 2007). On the other hand, uptake 
of bLF in Caco-2 cells might be more effective than 
hLF as demonstrated by Shin et al. (2008), who stud-
ied the interaction between human and bovine LF 
and intelectin, a lectin present on the brush border 
of intestinal cells. Thus, internalized bLF could no 
longer prevent bacterial attachment to host cells.
Ochoa et al. (2003) demonstrated the effect of hu-
man lactoferrin on enteropathogenic E. coli (EPEC). 
Lactoferrin blocked EPEC-mediated actin polym-
erization in HEp2 cells and blocked EPEC-induced 
hemolysis. The mechanism of these actions was 
lactoferrin-mediated degradation of Type III se-
creted proteins necessary for bacterial contact and 
pore formation, particularly EspB. Lactoferrin is 
also responsible for the degradation of the Shigella 
TTSS proteins IpaB and IpaC (Gomez et al., 2003). 
In our study, lactoferrin degraded recombinant 
EHEC EspA and EspB, which indeed could con-
tribute to its anti-microbial activity.
In conclusion, the direct antibacterial effect of 
bLF on E. coli O157:H7 was stronger than for hLF. 
Nevertheless, both lactoferrins acted bacteriostati-
cally even at high LF concentrations (10 mg/ml), 
suggesting blocking of LF activity by a yet unknown 
bacterial defence mechanism. Additionally, both 
lactoferrins significantly inhibited E. coli O157:H7 
attachment to Caco-2 cells. However, hLF was more 
effective than bLF. This is maybe due to more efficient 
binding of bLF to intelectin on human enterocytes 
and subsequent uptake and thus removal of bLF from 
the extracellular environment. Inhibition of attach-
ment was at least partly due to the catalytic effect of 
lactoferrins on the type III secreted proteins EspA and 
EspB. Further research is needed into the use of LF for 
supporting human treatment and/or for preventing 
E. coli O157:H7 infections in ruminants.
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